Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Circulation

• Publication date

  2000-03-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.101.9.1013PMID 10704169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study.

  1999cited by this paper
• Integrin signaling: the platelet paradigm.

  1998cited by this paper
• Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population.

  1998cited by this paper
• PlA2 polymorphism and efficacy of aspirin.

  1998cited by this paper
• Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions.

  1998cited by this paper
• The poetry of genetics: or reading a genetic sequence--a literary model for cellular mechanisms.

  1998cited by this paper
• Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

  1997cited by this paper
• Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.

  1996cited by this paper
• A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.

  1996cited by this paper
• Flow cytometry: a clinical test of platelet function.

  1996cited by this paper
• Adhesion Receptors as Therapeutic Targets

  1995cited by this paper
• Pharmacokinetic Optimisation of the Treatment of Embolic Disorders

  1995cited by this paper
• Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry.

  1994cited by this paper
• Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen binding. I. Quantal activation of platelet subpopulations varies with adenosine diphosphate concentration.

  1994cited by this paper
• The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

  1992cited by this paper
• The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

  1992cited by this paper
• Endogenous platelet fibrinogen surface expression on activated platelets.

  1991cited by this paper
• Nomenclature of platelet‐specific antigens

  1990cited by this paper
• Platelet hyperreactivity and prognosis in survivors of myocardial infarction.

  1990cited by this paper
• Platelet hyperreactivity and prognosis in survivors of myocardial infarction.

  1990cited by this paper
• Nomenclature of platelet-specific antigens.

  1990cited by this paper
• Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers.

  1990cited by this paper
• A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation

  1985cited by this paper
• Kinetics of pharmacologic response.

  1982cited by this paper
• Reduction in Single Platelets During Primary and Secondary Aggregation

  1981cited by this paper
• Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation.

  1980cited by this paper
• Perspectives Series: Cell Adhesion in Vascular Biology Platelet Gpiib/iiia Antagonists: the First Anti-integrin Receptor Therapeutics

  year unknowncited by this paper

• Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes—Pharmacogenomic Impact on Inter‐Organ Communication

  2025cites this paper
• Current and Future Roles of Glycoprotein IIb–IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction

  2024cites this paper
• The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis

  2024cites this paper
• Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents.

  2024cites this paper
• DNA methylation profile in the whole blood of acute coronary syndrome patients with aspirin resistance

  2022cites this paper
• Enhanced Activation of Integrin αIIbβ3-Dependent Signaling in the Pro33 (HPA-1b) Variant

  2021cites this paper
• Pharmacodynamics and Pharmacokinetics of Stroke Therapy

  2021cites this paper
• PlA2 Polymorphism of Platelet Glycoprotein IIb/IIIa and C677T Polymorphism of Methylenetetrahydrofolate Reductase (MTHFR), but Not Factor V Leiden and Prothrombin G20210A Polymorphisms, Are Associated with More Severe Forms of Legg–Calvé–Perthes Disease

  2021cites this paper
• Updated understanding of platelets in thrombosis and hemostasis: the roles of integrin PSI domains and their potential as therapeutic targets.

  2020cites this paper
• Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis

  2019cites this paper
• Foreword: A Brief History of Ideas About Platelets in Health and Disease

  2019cites this paper
• Association between fibrinogen receptor (Glycoprotein IIb) polymorphism and the risk of venous thromboembolism: a systematic review

  2019cites this paper
• The Leu 33 Pro polymorphism in the gene does not modify-associated breast or ovarian cancer risks : results from a multicenter study among 15 , 542 and mutation carriers

  2018cites this paper
• Using flow cytometry to monitor glycoprotein IIb-IIIa activation

  2018cites this paper
• Leu33Pro (PlA) polymorphism of integrin beta3 modulates platelet Src pY418 and focal adhesion kinase pY397 phosphorylation in response to abnormally high shear stress

  2018cites this paper
• A novel ultrasonic method for evaluation of blood clotting parameters

  2018cites this paper
• Platelet glycoprotein gene Ia C807T, HPA-3, and Ibα VNTR polymorphisms are associated with increased ischemic stroke risk: Evidence from a comprehensive meta-analysis

  2017cites this paper
• Platelet genomics: the role of platelet size and number in health and disease

  2017cites this paper
• Gene Regulation of Platelet Function

  2017cites this paper
• Platelets and Polymorphisms

  2017cites this paper
• Pharmacogenomics of platelet inhibitors

  2016cites this paper
• Glycoprotein IIIa PlA 1 / A 2 Polymorphism and Sudden Cardiac Death

  2016cites this paper
• [Prevalence and prognosis of aspirin resistance in critical limb ischemia patients].

  2016cites this paper
• Integrin αIIbβ3-Dependent ERK Signaling Is Regulated by Src and Rho Kinases in Both Leu33 and Pro33 Polymorphic Isoforms

  2016cites this paper
• Prévalence et valeur pronostique de la résistance à l’aspirine chez les patients en ischémie critique chronique des membres inférieurs☆

  2016cites this paper
• Polimorfizmi u genima za koagulacijske čimbenike i enzime metabolizma homocisteina u djece s moždanim udarom

  2016cites this paper
• Aspirin Resistance Resistance In Vitro to Low-Dose Aspirin Is Associated With Platelet PlA 1 ( GP IIIa ) Polymorphism But Not With C 807 T ( GP Ia / IIa ) and C-5 T Kozak ( GP Ib ) Polymorphisms

  2016cites this paper
• Sticky platelet syndrome: an important cause of life-threatening thrombotic complications

  2016influential citation
• Potential Social, Ethical, and Legal Issues Raised by the Development of Pharmacogenetics

  2016cites this paper
• Platelet Glycoprotein IIb / IIIa PlA 2 / PlA 2 Homozygosity Associated With Risk of Ischemic Cardiovascular Disease and Myocardial Infarction in Young Men The Copenhagen City Heart Study

  2016cites this paper
• Common genetic variants in platelet surface receptors and its association with ischemic stroke.

  2016cites this paper
• Subpopulations in purified platelets adhering on glass.

  2016cites this paper
• Genetic markers: Potential candidates for cardiovascular disease.

  2016cites this paper
• Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus

  2015cites this paper
• Anti-human platelet antigen (HPA)-1a antibodies: For better or for worse

  2015cites this paper
• Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function

  2015cites this paper
• Impact of platelet phenotype on myocardial infarction

  2015cites this paper
• Multiple thrombophilic single nucleotide polymorphisms lack a significant effect on outcomes in fresh IVF cycles: an analysis of 1717 patients

  2015cites this paper
• Association of Platelet Glycoprotein Receptor Alpha2beta1 Integrin and Glycoprotein IIIa Gene Polymorphisms with Diabetic Retinopathy: Evidence from 3007 Subjects

  2015cites this paper
• Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: An Overview.

  2015cites this paper
• Glycoprotein Ia C807T: Polymorphisms and Their Association with Platelet Function in Patients with the Acute Coronary Syndrome

  2015cites this paper
• High On-Treatment Platelet Reactivity in Peripheral Endovascular Procedures

  2014cites this paper
• Pharmacodynamics- and Pharmacogenetics-Guided Antiplatelet Therapy

  2014cites this paper
• THE PHARMACOGENETICS OF CARDIOVASCULAR DRUGS

  2014cites this paper
• Relationships of glycoproteins IIb-IIIa and Ib content with mean platelet volume and their genetic polymorphisms

  2014cites this paper
• Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty

  2014cites this paper
• Mean platelet volume: Interrelation with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels

  2014cites this paper
• Pro 32 Pro 33 Mutations in the Integrin b 3 PSI Domain Result in a IIb b 3 Priming and Enhanced Adhesion : Reversal of the Hypercoagulability Phenotype by the Src Inhibitor SKI-606 s

  2014cites this paper
• [Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels].

  2014cites this paper
• Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects

  2014cites this paper
• The role of coagulation factor XII in fibrin clot formation and fibrinolysis

  2014cites this paper
• Platelet HPA-1 a/HPA-1 b polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI

  2014cites this paper
• Cardiovascular pharmacogenetics of anti-thrombotic agents and non-steroidal anti-inflammatory drugs.

  2014cites this paper
• Effects of Environmental, Genetic, and Epigenetic Factors on Platelet Glycoproteins and the Development of Diabetic Retinopathy

  2014cites this paper
• The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta‐analysis

  2014cites this paper
• Pro32Pro33 Mutations in the Integrin β3 PSI Domain Result in αIIbβ3 Priming and Enhanced Adhesion: Reversal of the Hypercoagulability Phenotype by the Src Inhibitor SKI-606

  2014cites this paper
• PLA1A2 platelet polymorphism predicts mortality in prediabetic subjects of the population based KORA S4-Cohort

  2014cites this paper
• Genetics of response to antiplatelet therapy.

  2014cites this paper
• Hemostasis and Thrombosis

  2013cites this paper
• A systematic review on pharmacogenetics in cardiovascular disease Is it ready for clinical application ?

  2013cites this paper
• long-term VAD support Clinical significance of PlA polymorphism of platelet GP IIb/IIIa receptors during

  2013cites this paper
• Psychiatry Platelets and depression in cardiovascular disease: A brief review of the current literature

  2013cites this paper
• Clinical Impact of Genetically Determined Platelet Reactivity

  2013cites this paper
• Genetic variation and cognitive dysfunction one year after cardiac surgery

  2013cites this paper
• Integrin &agr;IIb&bgr;3: From Discovery to Efficacious Therapeutic Target

  2013cites this paper
• The a1/a2 polymorphism of the glycoprotein IIIa gene and myocardial infarction in Caucasians with type 2 diabetes

  2013cites this paper
• Common Genetic Determinants of Coagulation and Fibrinolysis

  2013cites this paper
• Genetic variation of platelet function and pharmacology: An update of current knowledge

  2013cites this paper
• A Brief History of Ideas About Platelets in Health and Disease

  2013cites this paper
• Genetic and pharmacogenetic determinants of cardiovascular disease

  2013cites this paper
• 21 – Hemostatic Aspects of Cardiovascular Medicine

  2013cites this paper
• Sticky Platelet Syndrome and the Role of Glycoprotein Receptors: A Review of Literature

  2013cites this paper
• The Pharmacogenetics of Cardiovascular Drugs / FARMAKOGENETIKA KARDIOVASKULARNIH LEKOVA

  2013cites this paper
• Chapter 29 – Flow Cytometry

  2013cites this paper
• Republished article: Pharmacogenetics of antiplatelet therapy: ready for clinical application?

  2012cites this paper
• Glycoprotein IIb-IIIa inhibitors.

  2012cites this paper
• Glycoprotein IIb-IIIa inhibitors.

  2012cites this paper
• Genetic variants that affect platelet function

  2012cites this paper
• The role of genetics in pre-eclampsia and potential pharmacogenomic interventions

  2012cites this paper
• Resistance to low‐dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors

  2012cites this paper
• Antithrombotic Therapies in Primary Angioplasty

  2012cites this paper
• Elevated circulating aldosterone and platelet activity in overweight/obese young adults: Roles in vascular remodeling and cardiometabolic health

  2012cites this paper
• Pharmacogenetics of the antiplatelet effect of aspirin.

  2012cites this paper
• Platelets and depression in cardiovascular disease: A brief review of the current literature.

  2012cites this paper
• The Atherosclerosis Risk in Communities (ARIC) Study

  2011cites this paper
• Aspirin resistance in patients with acute coronary syndrome. Part 2

  2011cites this paper
• Public Health Genomics: Exploiting SNP-NSAID interactions to prevent colorectal cancer

  2011influential citation
• Novel Insights into Genetics of Arterial Thrombosis

  2011cites this paper
• Pharmacogenetics of antiplatelet therapy: ready for clinical application?

  2011cites this paper
• Controversies in cardiovascular medicine A systematic review on pharmacogenetics in cardiovascular disease : is it ready for clinical application ?

  2011cites this paper
• Platelet receptor polymorphisms do not influence Staphylococcus aureus–platelet interactions or infective endocarditis

  2011cites this paper
• Impact of PlA 2 Polymorphism on Cardiovascular Disease and Outcome after Percutaneous Coronary Intervention : A Review of Current Evidence and Future Perspectives

  2011cites this paper
• Platelet aggregation pathway.

  2011cites this paper
• Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome

  2011cites this paper
• strictly antiplatelet actions Antithrombotic properties of aspirin and resistance to aspirin: beyond

  2011cites this paper
• The pharmacogenetics of antiplatelet agents: towards personalized therapy?

  2011cites this paper
• A1/A2 polymorphism of the glycoprotein IIIa gene and diabetic retinopathy in Caucasians with type 2 diabetes

  2011cites this paper
• Association of the platelet GPIIb/IIIa polymorphism with atherosclerotic plaque morphology: the Atherosclerosis Risk in Communities (ARIC) Study.

  2011cites this paper
• Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.

  2011cites this paper
• Impact of PlA2 Polymorphism on Cardiovascular Disease and Outcome after Percutaneous Coronary Intervention: A Review of Current Evidence and Future Perspectives

  2011cites this paper